Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

October 2nd, 2026

Post Hoc SOLARIS Data Support Stabilization and Remission With Subcutaneous Olanzapine

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

October 1st, 2026

Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

October 1st, 2026

Presenting Our October 2026 Theme: PTSD

Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.

September 30th, 2026

VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027

Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.

September 30th, 2026

Nature vs Nurture: The Interplay Between Genetics and Environmental Influences

How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.

September 30th, 2026

Researchers Call for Evidence and Guidelines on Telehealth Buprenorphine for Perinatal Opioid Use Disorder

Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.

November 2009 Table of Contents

Articles in this issue

Related to this article

Trending on Psychiatric Times

Interventional Options for TRD: ECT, TMS, and Esketamine

Defining Treatment-Resistant Depression In Adults